A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

Lee P. Resta, Roberto Pili, Mario A. Eisenberger, Avery Spitz, Serina King, Jennifer Porter, Amy Franke, Ramesh Boinpally, Michael A. Carducci, Christopher J. Sweeney

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods: This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m2 given on Day 1 of each 21-day cycle. Results: OSI-461 dose was escalated to 1,000 mg po bid. One patient experienced a dose-limiting toxicity (DLT). Three patients discontinued the study due to adverse events (AE). Two patients (10%) had a partial response, and ten patients (50%) had stable disease as best response. Conclusion The combination of OSI-461 and mitoxantrone was well tolerated. Dose escalation was stopped because of toxicities in a concurrent Phase I trial. The response rate seen in patients with prostate cancer was comparable to response rates seen in trials of mitoxantrone and prednisone alone, and further studies of the combination of OSI-461 and mitoxantrone were not pursued.

Original languageEnglish (US)
Pages (from-to)431-438
Number of pages8
JournalCancer Chemotherapy and Pharmacology
Volume67
Issue number2
DOIs
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Mitoxantrone
Tumors
Neoplasms
Toxicity
Prednisone
Maximum Tolerated Dose
(5-fluoro-2-methyl-1-(4-pyridyl)methylene-3-(N-benzyl)-indene)-acetamide hydrochloride
Prostatic Neoplasms
Cohort Studies

Keywords

  • Apoptosis
  • Clinical trial
  • Mitoxantrone
  • OSI-461

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. / Resta, Lee P.; Pili, Roberto; Eisenberger, Mario A.; Spitz, Avery; King, Serina; Porter, Jennifer; Franke, Amy; Boinpally, Ramesh; Carducci, Michael A.; Sweeney, Christopher J.

In: Cancer Chemotherapy and Pharmacology, Vol. 67, No. 2, 02.2011, p. 431-438.

Research output: Contribution to journalArticle

Resta, LP, Pili, R, Eisenberger, MA, Spitz, A, King, S, Porter, J, Franke, A, Boinpally, R, Carducci, MA & Sweeney, CJ 2011, 'A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone', Cancer Chemotherapy and Pharmacology, vol. 67, no. 2, pp. 431-438. https://doi.org/10.1007/s00280-010-1328-7
Resta, Lee P. ; Pili, Roberto ; Eisenberger, Mario A. ; Spitz, Avery ; King, Serina ; Porter, Jennifer ; Franke, Amy ; Boinpally, Ramesh ; Carducci, Michael A. ; Sweeney, Christopher J. / A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone. In: Cancer Chemotherapy and Pharmacology. 2011 ; Vol. 67, No. 2. pp. 431-438.
@article{f343cb154c424bbbbb21c8dfa1ff21b2,
title = "A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone",
abstract = "Purpose: To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods: This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m2 given on Day 1 of each 21-day cycle. Results: OSI-461 dose was escalated to 1,000 mg po bid. One patient experienced a dose-limiting toxicity (DLT). Three patients discontinued the study due to adverse events (AE). Two patients (10{\%}) had a partial response, and ten patients (50{\%}) had stable disease as best response. Conclusion The combination of OSI-461 and mitoxantrone was well tolerated. Dose escalation was stopped because of toxicities in a concurrent Phase I trial. The response rate seen in patients with prostate cancer was comparable to response rates seen in trials of mitoxantrone and prednisone alone, and further studies of the combination of OSI-461 and mitoxantrone were not pursued.",
keywords = "Apoptosis, Clinical trial, Mitoxantrone, OSI-461",
author = "Resta, {Lee P.} and Roberto Pili and Eisenberger, {Mario A.} and Avery Spitz and Serina King and Jennifer Porter and Amy Franke and Ramesh Boinpally and Carducci, {Michael A.} and Sweeney, {Christopher J.}",
year = "2011",
month = "2",
doi = "10.1007/s00280-010-1328-7",
language = "English (US)",
volume = "67",
pages = "431--438",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - A Phase I study of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors potentially responsive to mitoxantrone

AU - Resta, Lee P.

AU - Pili, Roberto

AU - Eisenberger, Mario A.

AU - Spitz, Avery

AU - King, Serina

AU - Porter, Jennifer

AU - Franke, Amy

AU - Boinpally, Ramesh

AU - Carducci, Michael A.

AU - Sweeney, Christopher J.

PY - 2011/2

Y1 - 2011/2

N2 - Purpose: To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods: This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m2 given on Day 1 of each 21-day cycle. Results: OSI-461 dose was escalated to 1,000 mg po bid. One patient experienced a dose-limiting toxicity (DLT). Three patients discontinued the study due to adverse events (AE). Two patients (10%) had a partial response, and ten patients (50%) had stable disease as best response. Conclusion The combination of OSI-461 and mitoxantrone was well tolerated. Dose escalation was stopped because of toxicities in a concurrent Phase I trial. The response rate seen in patients with prostate cancer was comparable to response rates seen in trials of mitoxantrone and prednisone alone, and further studies of the combination of OSI-461 and mitoxantrone were not pursued.

AB - Purpose: To find the maximum tolerated dose (MTD) of OSI-461 in combination with mitoxantrone in patients with advanced solid tumors. Methods: This was a Phase I study using cohort dose escalation of OSI-461 dosed orally twice daily in combination with mitoxantrone 12 mg/m2 given on Day 1 of each 21-day cycle. Results: OSI-461 dose was escalated to 1,000 mg po bid. One patient experienced a dose-limiting toxicity (DLT). Three patients discontinued the study due to adverse events (AE). Two patients (10%) had a partial response, and ten patients (50%) had stable disease as best response. Conclusion The combination of OSI-461 and mitoxantrone was well tolerated. Dose escalation was stopped because of toxicities in a concurrent Phase I trial. The response rate seen in patients with prostate cancer was comparable to response rates seen in trials of mitoxantrone and prednisone alone, and further studies of the combination of OSI-461 and mitoxantrone were not pursued.

KW - Apoptosis

KW - Clinical trial

KW - Mitoxantrone

KW - OSI-461

UR - http://www.scopus.com/inward/record.url?scp=79953789744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953789744&partnerID=8YFLogxK

U2 - 10.1007/s00280-010-1328-7

DO - 10.1007/s00280-010-1328-7

M3 - Article

C2 - 20445979

AN - SCOPUS:79953789744

VL - 67

SP - 431

EP - 438

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -